Novo Nordisk Raises Guidance Amid Surging Demand for Diabetes, Obesity Drugs
[ad_1] Novo Nordisk now expects 2023 sales growth of 27%-33% and operating profit growth of 31%-37%, as demand for its…
Diabetes
Read More
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New Study
[ad_1] Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20%. [ad_2] Source…
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New Study
[ad_1] Novo Nordisk’s anti-obesity drug reduced people’s risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a…
New Venture Fund Targets Innovations in Blood Research
[ad_1] New York Blood Center, a nonprofit that provides services to patients and conducts research in blood diseases, has launched…